“Latest Stem Cells News”

In a major achievement, the scientists have managed to get a patent for growing stem cells of the cornea. The cells will be grown on a synthetic material, called Mebiol Gel, which will be used in the process of transplant.

For a long time scientists across the world have been trying to get the patent. The declaration was made by the researchers at Sankara Nethralaya and Nichi-In Biosciences Sankara Nethralaya and Nichi-In Biosciences on Friday.

The new procedures have been devised and patented by these two institutes. A synthetic substance was used by the researchers for growing the corneal limbal stem cells in order to reduce the chances of viral infections. Moreover, biological materials have a greater chance of rejection.

Incoming search terms:

Dozens of people who were blinded or otherwise suffered severe eye damage when they were splashed with caustic chemicals had their sight restored with transplants of their own stem cells — a stunning success for the burgeoning cell-therapy field, Italian researchers reported Wednesday.

The treatment worked completely in 82 of 107 eyes and partially in 14 others, with benefits lasting up to a decade so far. One man whose eyes were severely damaged more than 60 years ago now has near-normal vision.

“This is a roaring success,” said ophthalmologist Dr. Ivan Schwab of the University of California, Davis, who had no role in the study — the longest and largest of its kind.

Stem cell transplants offer hope to the thousands of people worldwide every year who suffer chemical burns on their corneas from heavy-duty cleansers or other substances at work or at home.

The approach would not help people with damage to the optic nerve or macular degeneration, which involves the retina. Nor would it work in people who are completely blind in both eyes, because doctors need at least some healthy tissue that they can transplant.

Incoming search terms:

Nerve stem cell transplants may help slow the progression of macular degeneration, the most common cause of blindness in the developed world, U.S. researchers said on Monday.

They said putting nerve stem cells from StemCells Inc near the retinas of rats with a form of macular degeneration helped keep the disease from advancing to blindness for several months.

“These cells improve the chemical environment in the back of the eye,” said Ray Lund of the Casey Eye Institute at Oregon Health & Science University in Portland, whose findings were presented at the Society for Neuroscience meeting in Chicago.

Lund said the mechanism is not clear, but he suspects that when immature nerve cells are placed near the retina, they produce growth factors that protect the cells from damage by the disease.

Incoming search terms:

A technique that combines nanotechnology with adult stem cells appears to destroy atherosclerotic plaque and rejuvenate the arteries, according to a study reported at the American Heart Association‘s Basic Cardiovascular Sciences 2010 Scientific Sessions – Technological and Conceptual Advances in Cardiovascular Disease.

In the study, nanoparticles (microscopic particles with at least one dimension less than 80 nm) were infused into the heart of pigs along with adult stem cells. After the nanoparticles were heated by laser light, they burned away arterial plaque. However, nanoparticles were less effective at eliminating plaque if not combined with adult stem cells.

“This unique approach holds promise for use in humans for acute care and urgent restoration of blood flow,” said Alexandr Kharlamov, M.D., lead author and research manager at the Department of Internal Medicine and Research Center of Regenerative Medicine, Ural State Medical Academy in Yekaterinburg, Russian Federation. “Biophotonics (light therapy), plasmonics (plasma therapy), stem cell therapy and nanotechnology might someday offer a completely novel treatment to reduce artery plaque build-up.”

Incoming search terms:

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that it has been awarded a $700,000 contract from the U.S. Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center (USAMRMC-TATRC) under U.S. Army Medical Research Acquisition Activity contract number: (W81XWH-10-2-0039).

This contract is for the purpose of evaluating the use of topically applied bone marrow-derived adult mesenchymal stem cells (MSCs) for rapid wound healing. The Company previously announced that this funding was included in the Department of Defense FY09 Appropriations Bill and will begin receiving funds to initiate the program in 2010.

“NeoStem is thrilled to have the United States Government’s support to advance our technology and is honored to become part of TATRC’s regenerative medicine portfolio. It is our goal with this important project to leverage adult stem cell technology to help our soldiers avoid amputations and immobilization from injuries that they may sustain while fighting for our country.

Incoming search terms:

DURHAM — To donate the stem cell-rich umbilical cord blood produced during the birth of her daughter, Jaime Feaster of Lake Charles, La., would have had to drive more than two hours to the nearest hospital equipped to collect it.

That’s a long way to go when you’re in labor.

Instead, Feaster turned to a fledgling Duke University Medical Center program that provides collection kits to mothers and their doctors. When Feaster’s daughter, Kadee, arrived last month, the cord blood was collected, packaged and quickly shipped to a blood bank at no cost to Feaster and with minimal commitment of time and expertise from her doctor.

Duke doctor Joanne Kurtzberg wants to replicate Feaster’s experience on a large scale.

Kurtzberg hopes that an easier donation process will trigger a surge in donations of blood cells so valuable they’ve been used to reverse and even cure otherwise fatal disorders. The current cord blood supply can’t keep up with the demand for its use in treating leukemia, sickle cell disease and other blood disorders, and the nation’s hospital infrastructure isn’t set up to tap even a fraction of the potential donors.

Incoming search terms: